Klunk, William E MD
University of Pittsburgh
Adults with Down syndrome (DS) are at an extremely high risk for developing Alzheimer's disease (AD), with most individuals over age 40 evidencing neurofibrillary tangles and neuritic plaques (which are thought to be associated with the eventual appearance of AD symptoms). The goal of the current application is to recruit and follow 180 adults with DS and 40 biomarker controls to enable the identification of the longitudinal progression of AD in adults with DS using clinical, cognitive, imaging and genetic and biochemical biomarkers. This data is not only necessary to deepen our understanding of the pathophysiology of AD in DS, but may also offer information that will prove useful in the design of treatment trials to slow or prevent AD in DS.